04:54 , Jan 19, 2018 |  BC Week In Review  |  Clinical News

Matinas' MAT2203 meets in Phase IIa for mucocutaneous candidiasis

Matinas BioPharma Holdings Inc. (NYSE-M:MTNB) reported data from three evaluable patients with chronic refractory mucocutaneous candidiasis in a Phase IIa trial showing that oral MAT2203 (CAmB) met the primary endpoint of reducing clinical symptoms. To...
23:16 , Jul 13, 2017 |  BC Week In Review  |  Clinical News

Matinas reports Phase II data of MAT2203 for vulvovaginal candidiasis

Matinas BioPharma Holdings Inc. (NYSE-M:MTNB) reported top-line data from a Phase II trial to treat moderate to severe vulvovaginal candidiasis showing that oral CAmB (MAT2203) met the primary safety endpoint but missed the secondary efficacy...
05:14 , Mar 31, 2017 |  BC Week In Review  |  Clinical News

MAT2501: Ph I data

Top-line data from a double-blind, placebo-controlled Phase I trial in 36 healthy volunteers showed that single ascending doses of oral MAT2501 were well tolerated with no serious adverse events reported. Matinas BioPharma Holdings Inc. (OTCQB:MTNB), Bedminster,...
19:53 , Jan 13, 2017 |  BC Week In Review  |  Clinical News

VT-1161: Additional Ph IIb REVIVE data

Additional data from the double-blind, U.S. Phase IIb REVIVE trial in 215 patients with recurrent vulvovaginal candidiasis showed that 150 and 300 mg doses of oral VT-1161 once daily for 7 days and then once...
19:53 , Jan 13, 2017 |  BC Week In Review  |  Clinical News

VT-1161: Additional Ph IIb RENOVATE data

Additional data from the double-blind, U.S. Phase IIb RENOVATE trial in 259 patients with distal lateral subungual onychomycosis of the large toenail showed that 300 and 600 mg doses of oral VT-1161 once daily for...
20:29 , Nov 23, 2016 |  BC Week In Review  |  Clinical News

MAT2203: Ph II started

Matinas began a single-blind, U.S. Phase II trial to compare 200 and 400 mg doses of oral MAT2203 to oral fluconazole in about 75 females with moderate to severe vulvovaginal candidiasis. Matinas BioPharma Holdings Inc. (OTCQB:MTNB),...
07:00 , Oct 17, 2016 |  BC Week In Review  |  Clinical News

VT-1161 regulatory update

FDA granted Qualified Infectious Disease Product (QIDP) designation to VT-1161 from Viamet to treat recurrent vulvovaginal candidiasis. VT-1161 is in a Phase IIb trial for the indication (see BioCentury, March 14). The product is an...
07:00 , Mar 14, 2016 |  BC Week In Review  |  Clinical News

VT-1161: Interim Phase IIb data

Interim data from about 100 patients with distal lateral subungual onychomycosis of the large toenail in the double-blind, U.S. Phase IIb RENOVATE trial showed that 300 and 600 mg oral VT-1161 once daily for 2...
07:00 , Mar 14, 2016 |  BC Week In Review  |  Clinical News

VT-1161: Interim Phase IIb data

Interim data from about 100 patients with recurrent vulvovaginal candidiasis in the double-blind, U.S. Phase IIb REVIVE trial showed that 150 and 300 mg oral VT-1161 once daily for 7 days and then once-weekly for...
08:00 , Feb 22, 2016 |  BC Week In Review  |  Clinical News

CAmB: Phase IIa started

Matinas said the NIH began an open-label, U.S. Phase IIa trial to evaluate oral MAT2203 for 14 days in up to 16 patients who are refractory or intolerant to standard non-IV therapies. Matinas BioPharma Holdings...